• Publications
  • Influence
PAINFUL DIABETIC PERIPHERAL NEUROPATHY : A STEPWISE APPROACH TO TREATMENT
The stepwise approach to the treatment of painful diabetic peripheral neuropathy allows the practitioner to use a broad spectrum of therapeutic modalities and physiologic approaches to thisExpand
  • 12
  • 1
NAC: first controlled trial, positive results.
: At the May 21-24, 1996 meeting, Oxidative Stress and Redox Regulation: Cellular Signaling, AIDS, Cancer and Other Diseases, held at the Institut Pasteur in Paris, researchers reported the resultsExpand
  • 5
  • 1
Low vitamin B-12 blood levels associated with faster progression to AIDS.
: A Johns Hopkins study of more than 300 men indicated that those with an abnormally low level of vitamin B-12 in their blood serum progressed to AIDS almost twice as fast as those with normalExpand
  • 2
  • 1
Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers.
: Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the Food and Drug Administration (FDA) for use in combination with one orExpand
  • 7
Lamivudine (3TC) approved for combination use with AZT.
: The Food and Drug Administration (FDA) used accelerated approval regulations to approve the use of Glaxo-Wellcome's lamivudine (Epivir/3TC) in combination with AZT. The FDA guidelines used forExpand
  • 4
Stanford NAC study: glutathione level predicts survival.
: CD4 cells with low levels of glutathione, a biochemical that protects cells from oxidative stress, have been found to be predictive of poor survival. A randomized study of N-acetyl-cysteine, a drugExpand
  • 6
Wasting syndrome--affordable treatments.
: Inexpensive potential treatments are available for wasting syndrome in AIDS, and early experience suggests that most patients can be successfully treated by using one or another of them. This mayExpand
  • 2
Valacyclovir study stopped -- worse survival.
: A study (ACTG 204) involving the effect of valacyclovir in preventing CMV disease in persons with advanced HIV infection (CD4 count under 100) was stopped because there were more deaths in theExpand
  • 1
Editorial: time to end the death trials.
: The current system of clinical trials for AIDS drugs mandates serious mismanagement of research because most of the resources are spent on trials that do not answer practical questions for doctorsExpand
  • 1
Protease inhibitors: drug resistance and cross resistance overview.
: Viral resistance to protease inhibitors, particularly saquinavir, is a problem. The background of this resistance, what is known about it, and questions concerning saquinavir dosage and formulationExpand
  • 2